Supply Chain Archives
12/22/2025
Celebrating Innovation at the Cryoport Systems Grand Opening in Louvres, France
Cryoport Systems recently opened the doors of its newest Global Supply Chain Center (GSCC) in Louvres, France, marking a major step forward in how cell and gene therapies move safely and compliantly across Europe and the world. Strategically located just outside Paris and minutes from Charles de Gaulle Airport (CDG), this GSCC strengthens our integrated network and brings critical capabilities closer to sponsors, CROs, CDMOs, and clinical sites throughout the region, and strengthens our support of regional animal health and reproductive medicine organizations.
12/19/2025
Expert Q&A: Is Standardization the Bottleneck or Breakthrough to Building Scalable and Cost-Effective CGT Programs?
Cell and gene therapy (CGT) companies are under constant pressure to do more while hitting milestones earlier. Demonstrate manufacturability. Ensure regulatory readiness. Design for scalability and patient access. And do all of this with more constrained resources and increasingly aggressive timelines. Building on our recent panel discussion, we gathered extended perspectives from Dr. Don Fink (Dark Horse Consulting Group), Audrey Greenberg (Mayo Venture Partners), Dr. Dominic Clarke (Cryoport Systems), and Kurtis Carlisle (Cabaletta Bio).
12/17/2025
2025 Year in Review: Turning Standards and Resilience into Outcomes
If you work within the advanced therapy ecosystem, you already know the story of 2025 from an industry standpoint, where science continued accelerating while funding and commercialization hinged on whether the supporting systems could keep up. For Cryoport Systems, that reality was a catalyst. This year, we raised the bar yet again and demonstrated how having the right strategic partnership behind your end-to-end supply chain can turn logistics into leverage, can transform compliance into confidence, and can spin scale into speed.
12/17/2025
A Look Back at 2025 in Animal Health
Innovation is quickly outpacing regulation and driving the development of specialized medicine for the animal health industry. These advanced therapies and next-generation biologics are coming to market at a pace that demands precision and agility despite the lack of clear guidelines. In this complex environment, the dependability of your logistics strategy can determine future scalability and commercial success even before your product leaves the lab. The pre-clinical and initial trial phases are the ideal time to set the stage for growth, as building reliable, compliance-aligned processes early helps keep materials stable, data credible, and operations ready to evolve as your trials progress.
12/16/2025
Driving Compliance and Standardization in CGT Supply Chains
As cell and gene therapies (CGTs) continue to advance and more therapies reach late-stage clinical trials and commercialization, the complexity of the related logistics is only increasing. Therapies are crossing borders, reaching broader patient populations, and expanding into global distribution, all of which introduces risk if standards are inconsistent. Compliance and standardization, as a result, are essential for ensuring both scalability and patient safety.
12/15/2025
Lab to Market: A Trusted Logistics Strategy for Early-Phase Clinical Trials
Innovation is quickly outpacing regulation and driving the development of specialized medicine for the animal health industry. These advanced therapies and next-generation biologics are coming to market at a pace that demands precision and agility despite the lack of clear guidelines. In this complex environment, the dependability of your logistics strategy can determine future scalability and commercial success even before your product leaves the lab. The pre-clinical and initial trial phases are the ideal time to set the stage for growth, as building reliable, compliance-aligned processes early helps keep materials stable, data credible, and operations ready to evolve as your trials progress.
12/11/2025
Setting the Benchmark for Quality in Cell and Gene Therapy Logistics
Quality in cell and gene therapy (CGT) is the foundation that determines whether a therapy reaches a patient intact and effective. As the industry increasingly scales from early development of CGTs to global commercialization, the margin for error narrows as volume and complexity increase. Standards like ISO 21973 provide a framework, but true industry leadership comes from how those standards are applied. In this, Cryoport Systems is setting that benchmark.
12/09/2025
What is ISO 21973 and Why It Matters for Cell and Gene Therapy
Cell and gene therapies (CGTs) are transforming medicine, but the complexity of these treatments introduces new challenges for supply chain management. Every shipment represents a therapy that could change or save a life, which is a level of responsibility that demands precision and transparency, as well as standards that leave absolutely no room for error. ISO 21973:2020 was created to meet that need.
11/11/2025
